Sparsentan Provides Better Proteinuria Reduction in FSGS
BOSTON — Sparsentan, a first-in-class, oral dual endothelin-angiotensin receptor antagonist, shows significant benefit in reducing proteinuria in the difficult-to-manage focal segmental glomerulosclerosis (FSGS) compared with the angiotensin II receptor blocker (ARB) irbesartan, a new post-hoc analysis of the phase 3 DUPLEX trial shows. “Dual endothelin angiotensin receptor blockade with sparsentan led to partial or complete … Read more